Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

11.70 -0.22 (-1.85%)
Streaming Delayed Price Updated: 3:35 PM EDT, Sep 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,050,783
Open 11.87
Bid (Size) 11.69 (400)
Ask (Size) 11.71 (300)
Prev. Close 11.92
Today's Range 11.19 - 11.97
52wk Range 1.980 - 15.10
Shares Outstanding 33,577,873
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
From Pomerantz LLP
Via GlobeNewswire
News headline image
IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire

Performance

YTD
+115.5%
+115.5%
1 Month
-14.0%
-14.0%
3 Month
+16.5%
+16.5%
6 Month
+31.3%
+31.3%
1 Year
+470.7%
+470.7%

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
From Holzer & Holzer
Via GlobeNewswire
News headline image
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Participate in Upcoming Investor Conferences
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities ↗
Via Benzinga
News headline image
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗
Via Stocktwits
Topics ETFs Economy Government
News headline image
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Immix Biopharma, Inc. - Common Stock publicly traded?
Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Immix Biopharma, Inc. - Common Stock trade on?
Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?
The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market
What is the current price of Immix Biopharma, Inc. - Common Stock?
The current price of Immix Biopharma, Inc. - Common Stock is 11.70
When was Immix Biopharma, Inc. - Common Stock last traded?
The last trade of Immix Biopharma, Inc. - Common Stock was at 09/24/26 03:35 PM ET
What is the market capitalization of Immix Biopharma, Inc. - Common Stock?
The market capitalization of Immix Biopharma, Inc. - Common Stock is 392.86M
How many shares of Immix Biopharma, Inc. - Common Stock are outstanding?
Immix Biopharma, Inc. - Common Stock has 393M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.